Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

About this update from Jazz Pharmaceuticals Plc

[{"type":"text","content":"– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"– Expect 2026 total revenues of $4.25 to $4.50 billion –","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026.","length":198,"tagName":"p"},{"type":"text","content":""2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "In the fourth quarter, our disciplined execution resulted in $1.2 billion in revenue, reflecting 10% year-over-year growth and our highest revenue quarter ever. This performance provides us with strong momentum into 2026, as we prepare for the potential launch of zanidatamab in GEA, sustain launch execution for Modeyso and Zepzelca®, and reinforce the differentiated profiles of Epidiolex and Xywav as the leading branded treatments for epilepsy and narcolepsy, respectively. In parallel, we continue to advance our pipeline and pursue a corporate development strategy aligned with our rare disease focus that supports durable growth and long-term value creation for patients and shareholders."","length":1004,"tagName":"p"},{"type":"text","content":""Jazz had a transformative year across our R&D pipeline, led by the HERIZON-GEA-01 data, which we believe firmly positions zanidatamab as the HER2-targeted agent of choi...

More updates from Jazz Pharmaceuticals Plc